A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab

Baylor Akhavan; Wolfram E. Samlowski

doi:10.3389/fimmu.2026.1729883

January 29, 2026Frontiers in ImmunologyOpen Access

A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab

View Full Paper

Ask AI

Bookmark

Share

Key Points

Low tumor mutation burden and expression of pd-l1 are linked to poor progression-free survival in metastatic melanoma patients.
Patients with low tmb and high pd-l1 levels have limited responses to first-line ipilimumab plus nivolumab treatment.
Assessment of predictive biomarkers highlights the potential of developing a nomogram for better treatment outcomes.
Further research is needed to validate these findings and enhance predictive accuracy for immunotherapy benefits.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational analysis shows low tumor mutation burden and pd-l1 predict poor progression-free survival in metastatic melanoma, suggesting need for better predictive tools.

Abstract

Tumor mutation burden and PD-L1 represent potential predictive biomarkers for response to combination CKI therapy, while LDH and BRAF offer limited predictive value. Further work will be needed to develop a predictive nomogram to better aid in predicting potential immunotherapy benefit.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Akhavan et al. (2026) studied this question.

synapsesocial.com/papers/69a75c7ec6e9836116a256a3 https://doi.org/10.3389/fimmu.2026.1729883

View Full Paper

Ask AI

Bookmark

Share

A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading